Updated:
DNA Capital
DNA Capital was founded in 2009 and operates as the single-family office for the Bueno family. The underlying wealth originated from the family’s creation and...
DNA Capital
DNA Capital was founded in 2009 and operates as the single-family office for the Bueno family. The underlying wealth originated from the family’s creation and 2012 sale of Amil, a Brazilian healthcare insurer, to UnitedHealth Group. The firm targets early-stage through late-stage opportunities in healthcare. It deploys capital via direct co-investments and SPVs. Confirmed geographies include Brazil, the United States and other markets in North America and South America. The office also maintains exposure to AI/ML applications within its healthcare focus. No public AUM figure exists. The team is based in Montreal. Recent activity includes the May 2026 acquisition by DNA Partners of a majority stake in Circle Sales & Import. The office maintains a hybrid structure that combines family capital with third-party mandates through its affiliated private-equity and advisory divisions, creating a distinct sourcing and deployment model compared with pure single-family offices.
General information
Firm type
Single Family Office
Year founded
2009
Location
Region
North America
Country
Canada
City
Montréal
Corporate office
1000 rue Sherbrooke Ouest, Bureau 2500, Montréal, QC H3A 3G4
Principals
Daniel Labrecque
PDG et Représentant de courtier
Jean-Marc Bougie
Chef de la direction
Gian Carlo Di Tommaso
Associé
Sector focus
Frequently asked questions
Who runs investment decisions at DNA Capital?
Daniel Labrecque serves as PDG and broker representative. Jean-Marc Bougie acts as chief executive. Gian Carlo Di Tommaso and other partners participate in investment decisions.
How does DNA Capital source proprietary deal flow?
The firm leverages the Bueno family’s healthcare network and relationships built through the Amil transaction. It also draws on a group of operating advisors who serve on portfolio company boards.
Does DNA Capital participate in fund commitments or only direct deals?
DNA Capital structures investments primarily through direct co-investments and SPVs. It does not emphasize broad fund commitments.
What investment stages does DNA Capital typically target?
The firm covers seed through late stage, with emphasis on growth and late-stage healthcare opportunities.
Where does the underlying wealth come from?
The capital originates from the Bueno family’s build-and-sale of Amil, a Brazilian healthcare insurer acquired by UnitedHealth Group in 2012.
Which sectors does DNA Capital explicitly avoid?
No explicit avoidance list is published. Activity remains concentrated in healthcare services, InsurTech and digital health.
How is DNA Capital related to DNA Capital Holdings Inc.?
DNA Capital operates under the DNA Capital Holdings Inc. umbrella, which also houses advisory and private-client asset-management divisions.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: